Study hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.
Female patients, age>= 18 yrs, diagnosed with primary or advanced breast cancer
LumA or ER-positive Lobular subtypes
candidates to surgery as first treatment regardless of cN
ER-positive Her2 negative BC with ki67>10%
ER-negative tumors
Pregnancy;
Contraindication to PET;
Contraindication to MRI;
Single group
FES
Drug16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
PET/MRI A
Procedure/SurgeryAn additional FES PET/MRI will be performed before surgery.
Translational analysis
GeneticSelected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
Sensitivity of FES PET/MRI in detecting macrometastatic axillary lymph nodes
Ability of FES PET/MRI to detect macrometastatic (tumor deposit\>2mm) axillary lymph nodes in BC patients with LumA or Lob who are candidates to primary surgery.
Click on the lead sponsor to view all of their trials.
Università Vita-Salute San Raffaele
Lead sponsor
IRCCS San Raffaele
Sponsor institution
IRCCS San Raffaele
Collaborator
